akinbostanci Introduction Moderna, Inc.'s (NASDAQ:MRNA) stock has been sluggish this past year, returning -27%. In fact, Moderna was reportedly the "most shorted S&P 500 healthcare stock in July." My last analysis focused on the company's prospects, with their COVID-19/influenza combination vaccine targeting an $8 billion-plus market. My January analysis maintained a long-term perspective, culminating in a "strong buy" recommendation, noting: The pandemic-induced revenues only scratched the surface of Moder ...